FDA says it will limit access to Covid-19 boosters for Americans under 65

Critics say shift will negatively affect people who are not high risk but want to be vaccinated against the disease

The Food and Drug Administration (FDA) announced on Tuesday that it will limit access to seasonal Covid-19 boosters for healthy Americans under 65 without clear evidence of clinical benefit - a shift, critics say, that will make access difficult for people who are not high risk but want to be vaccinated against the disease.

Top officials at the FDA outlined a new framework for approving Covid-19 vaccines, saying that the US would make the boosters available for Americans over the age of 65 and for adults and children above the age of 6 months with at least one condition that increases their risk of severe Covid-19.